SLU-PP-332 100mg x120 Capsules

SLU-PP-332 is an ERRα (Estrogen-Related Receptor alpha) and ERRγ agonist that activates the transcriptional programs of endurance exercise adaptation in skeletal muscle — earning it the nickname "exercise in a pill" in research circles after its characterization by the Bhupinder Bhatt laboratory at Washington University. Unlike AICAR (which activates AMPK signaling) or PPAR delta agonists (which activate fatty acid oxidation pathways), SLU-PP-332 acts at the upstream nuclear receptor level to coordinate the full transcriptional program of aerobic adaptation that endurance training induces — including mitochondrial biogenesis, oxidative fiber-type switching, angiogenesis in muscle, and increased VO2 capacity.

ERRα and ERRγ are orphan nuclear receptors that regulate energy metabolism gene expression without requiring a classical lipid or hormone ligand. In skeletal muscle, ERRα/γ activation drives the expression of the complete transcriptional network that coordinates aerobic muscle adaptation: PGC-1α co-activation (the master mitochondrial biogenesis regulator), VEGF expression for muscle angiogenesis, genes encoding mitochondrial respiratory chain components, fatty acid β-oxidation enzymes, and the transcription factors that drive type II→type I oxidative fiber conversion. This coordinated transcriptional program is identical to what endurance exercise training achieves through repeated calcium/CAMKII and AMPK signaling — SLU-PP-332 bypasses the upstream signaling and directly activates the nuclear receptor that coordinates the downstream gene expression.

2023 preclinical data from Washington University demonstrated striking results: SLU-PP-332 administration to sedentary, obese mice produced measurable improvements in running capacity without additional exercise training, with gene expression analysis confirming ERRα/γ target gene activation across the skeletal muscle metabolic gene network. Treated mice showed increased skeletal muscle oxidative fiber content, higher mitochondrial density, and better metabolic parameters (glucose tolerance, body composition) compared to vehicle-treated controls — all without any forced exercise intervention.

The clinical relevance extends beyond athletic performance. ERRα/γ activation in cardiac muscle may provide cardioprotective metabolic benefits by improving cardiac energy efficiency (the heart uses ERRα/γ signaling extensively for its constant aerobic demands). In metabolic disease, ERRα/γ agonism improves skeletal muscle insulin sensitivity through increased mitochondrial capacity and oxidative metabolism. In aging, where sarcopenia (muscle wasting) and declining VO2max are consequences of diminished mitochondrial biogenesis, SLU-PP-332 may counter the muscle quality decline that accelerates age-related functional loss.

The 120-capsule supply provides 4 months at 100mg/day — the standard long-term research dosing supply. Oral bioavailability has been confirmed in preclinical pharmacokinetics. No human clinical data is yet available; this is a research compound reflecting the cutting edge of exercise mimetic pharmacology.